2 results
Not approvedWill not start
Primary: To evaluate local tumour control by using HIFU technology.Secondary: To evaluate treatment toxicity, disease progression and QoL.
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…